News | November 07, 2022
Balaxi Pharmaceuticals delivers strong growth in Q2 FY23
Revenue is up 23% whereas Profit After Tax expands 29% for the company
Revenue is up 23% whereas Profit After Tax expands 29% for the company
Saroglitazar Mg is an investigational compound in the USA/EU, undergoing Phase 2b/3 clinical trials in patients with Primary Biliary Cholangitis and Phase 2b in patients with Non- alcoholic Steatohepatitis
Innovative Capsugel Enprotect capsule can simplify the manufacturing process to accelerate drug development and expedite first-in-human timelines
Approval based on HIMALAYA Phase III trial results which showed single priming dose of Imjudo added to Imfinzi reduced risk of death by 22% vs. sorafenib
Availability of pharmaceutical-grade materials with broad API compatibility key to advancing drug delivery solutions
Ours is a story of India’s resilient public health system and of everyone working together as team India to battle the pandemic
Krsnaa Diagnostics plans to set up Tele-Pathology Reporting Centre in Pune
Celanese to conduct research, prototype development and characterization of a refillable contraceptive technology with award from the Bill & Melinda Gates Foundation
The WAVEsystem with the WAVEcontrol 4.0 embedded
An algorithm based testing for Fatty Liver Disease
Subscribe To Our Newsletter & Stay Updated
